Tefferi and Barbui divided patients with myelofibrosis and myeloid metaplasia into risk groups based on clinical and laboratory findings. This is based on a compilation of findings reported in the studies cited in the reference list. The authors are from the Mayo Clinic College of Medicine and Ospedale Riuniti in Bergamo, Italy.
Parameters:
(1) hemoglobin
(2) constitutional symptoms of hypercatabolism (fever, night sweats, unintended weight loss)
(3) circulating blasts
(4) WBC count
(5) cytogenetic abnormalities
|
Parameter |
Findings |
Points |
|
hemoglobin |
>= 10 g/dL |
0 |
|
|
< 10 g/dL |
1 |
|
constitutional symptoms |
none |
0 |
|
|
present |
1 |
|
circulating blasts |
< 1% (none or rare) |
0 |
|
|
>= 1% |
1 |
|
WBC count |
< 4,000 per µL |
1 |
|
|
4,000 - 30,000 per µL |
0 |
|
|
> 30,000 per µL |
1 |
|
cytogenetic abnormality |
13q- |
0 |
|
|
20q- |
0 |
|
|
other |
1 |
where:
• Some algorithms using hemoglobin give different cutoffs based on gender.
total risk score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the greater the risk.
|
Risk Score |
Risk |
Median Survival |
|
0 |
low |
> 10 years |
|
1 |
intermediate |
5-10 years |
|
2 to 5 |
high |
< 5 years |
Specialty: Hematology Oncology
ICD-10: ,
